Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

Chronic Kidney Disease Prognosis Consortium, Kunihiro Matsushita, Marije van der Velde, Brad C Astor, Mark Woodward, Andrew S Levey, Paul E de Jong, Josef Coresh, Ron T Gansevoort, Andrew S Levey, Meguid El-Nahas, Paul E de Jong, Josef Coresh, Kai-Uwe Eckardt, Bertram L Kasiske, Marcello Tonelli, Brenda Hemmelgarn, Josef Coresh, Brad C Astor, Kunihiro Matsushita, Yaping Wang, Robert C Atkins, Kevan R Polkinghorne, Steven J Chadban, Anoop Shankar, Ronald Klein, Barbara E K Klein, HaiYan Wang, Fang Wang, Luxia Zhang, Lisheng Liu, Michael Shlipak, Mark J Sarnak, Ronit Katz, Linda P Fried, Tazeen Jafar, Muhammad Islam, Juanita Hatcher, Neil Poulter, Nish Chaturvedi, Dietrich Rothenbacher, Hermann Brenner, Elke Raum, Wolfgang Koenig, Caroline S Fox, Shih-Jen Hwang, James B Meigs, Massimo Cirillo, Stein Hallan, Stian Lydersen, Jostein Holmen, Michael Shlipak, Mark J Sarnak, Ronit Katz, Linda P Fried, Paul Roderick, Dorothea Nitsch, Astrid Fletcher, Christopher Bulpitt, Brad C Astor, Josef Coresh, Takayoshi Ohkubo, Hirohito Metoki, Masaaki Nakayama, Masahiro Kikuya, Yutaka Imai, Ron T Gansevoort, Paul E de Jong, Marije van der Velde, Simerjot Kaur Jassal, Elizabeth Barrett-Connor, Jaclyn Bergstrom, David G Warnock, Paul Muntner, Suzanne Judd, William M McClellan, Mary Cushman, George Howard, Leslie A McClure, Sun Ha Jee, Heejin Kimm, Ji Eun Yun, Chi-Pang Wen, Sung-Feng Wen, Chwen-Keng Tsao, Min-Kuang Tsai, Johan Arnlöv, Brad C Astor, Priscilla Auguste, Josef Coresh, Ron T Gansevoort, Paul E de Jong, Kunihiro Matsushita, Marije van der Velde, Kasper Veldhuis, Yaping Wang, Mark Woodward, Laura Camarata, Beverly Thomas, Tom Manley, Chronic Kidney Disease Prognosis Consortium, Kunihiro Matsushita, Marije van der Velde, Brad C Astor, Mark Woodward, Andrew S Levey, Paul E de Jong, Josef Coresh, Ron T Gansevoort, Andrew S Levey, Meguid El-Nahas, Paul E de Jong, Josef Coresh, Kai-Uwe Eckardt, Bertram L Kasiske, Marcello Tonelli, Brenda Hemmelgarn, Josef Coresh, Brad C Astor, Kunihiro Matsushita, Yaping Wang, Robert C Atkins, Kevan R Polkinghorne, Steven J Chadban, Anoop Shankar, Ronald Klein, Barbara E K Klein, HaiYan Wang, Fang Wang, Luxia Zhang, Lisheng Liu, Michael Shlipak, Mark J Sarnak, Ronit Katz, Linda P Fried, Tazeen Jafar, Muhammad Islam, Juanita Hatcher, Neil Poulter, Nish Chaturvedi, Dietrich Rothenbacher, Hermann Brenner, Elke Raum, Wolfgang Koenig, Caroline S Fox, Shih-Jen Hwang, James B Meigs, Massimo Cirillo, Stein Hallan, Stian Lydersen, Jostein Holmen, Michael Shlipak, Mark J Sarnak, Ronit Katz, Linda P Fried, Paul Roderick, Dorothea Nitsch, Astrid Fletcher, Christopher Bulpitt, Brad C Astor, Josef Coresh, Takayoshi Ohkubo, Hirohito Metoki, Masaaki Nakayama, Masahiro Kikuya, Yutaka Imai, Ron T Gansevoort, Paul E de Jong, Marije van der Velde, Simerjot Kaur Jassal, Elizabeth Barrett-Connor, Jaclyn Bergstrom, David G Warnock, Paul Muntner, Suzanne Judd, William M McClellan, Mary Cushman, George Howard, Leslie A McClure, Sun Ha Jee, Heejin Kimm, Ji Eun Yun, Chi-Pang Wen, Sung-Feng Wen, Chwen-Keng Tsao, Min-Kuang Tsai, Johan Arnlöv, Brad C Astor, Priscilla Auguste, Josef Coresh, Ron T Gansevoort, Paul E de Jong, Kunihiro Matsushita, Marije van der Velde, Kasper Veldhuis, Yaping Wang, Mark Woodward, Laura Camarata, Beverly Thomas, Tom Manley

Abstract

Background: Substantial controversy surrounds the use of estimated glomerular filtration rate (eGFR) and albuminuria to define chronic kidney disease and assign its stages. We undertook a meta-analysis to assess the independent and combined associations of eGFR and albuminuria with mortality.

Methods: In this collaborative meta-analysis of general population cohorts, we pooled standardised data for all-cause and cardiovascular mortality from studies containing at least 1000 participants and baseline information about eGFR and urine albumin concentrations. Cox proportional hazards models were used to estimate hazard ratios (HRs) for all-cause and cardiovascular mortality associated with eGFR and albuminuria, adjusted for potential confounders.

Findings: The analysis included 105,872 participants (730,577 person-years) from 14 studies with urine albumin-to-creatinine ratio (ACR) measurements and 1,128,310 participants (4,732,110 person-years) from seven studies with urine protein dipstick measurements. In studies with ACR measurements, risk of mortality was unrelated to eGFR between 75 mL/min/1.73 m(2) and 105 mL/min/1.73 m(2) and increased at lower eGFRs. Compared with eGFR 95 mL/min/1.73 m(2), adjusted HRs for all-cause mortality were 1.18 (95% CI 1.05-1.32) for eGFR 60 mL/min/1.73 m(2), 1.57 (1.39-1.78) for 45 mL/min/1.73 m(2), and 3.14 (2.39-4.13) for 15 mL/min/1.73 m(2). ACR was associated with risk of mortality linearly on the log-log scale without threshold effects. Compared with ACR 0.6 mg/mmol, adjusted HRs for all-cause mortality were 1.20 (1.15-1.26) for ACR 1.1 mg/mmol, 1.63 (1.50-1.77) for 3.4 mg/mmol, and 2.22 (1.97-2.51) for 33.9 mg/mmol. eGFR and ACR were multiplicatively associated with risk of mortality without evidence of interaction. Similar findings were recorded for cardiovascular mortality and in studies with dipstick measurements.

Interpretation: eGFR less than 60 mL/min/1.73 m(2) and ACR 1.1 mg/mmol (10 mg/g) or more are independent predictors of mortality risk in the general population. This study provides quantitative data for use of both kidney measures for risk assessment and definition and staging of chronic kidney disease.

Funding: Kidney Disease: Improving Global Outcomes (KDIGO), US National Kidney Foundation, and Dutch Kidney Foundation.

Copyright 2010 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Flow chart for selection of articles.
Figure 2
Figure 2
HRs and 95% CIs for all-cause and cardiovascular mortality according to spline eGFR and ACR adjusted for each other, age, gender, race, CVD history, systolic blood pressure, diabetes, smoking, and total cholesterol. The reference was eGFR 95 ml/min/1·73 m2 and ACR 5 mg/g (0·6 mg/mmol), respectively. Dots represent statistically significant and triangles represent not significant.
Figure 3
Figure 3
HRs and 95% CIs for all-cause and cardiovascular mortality according to spline eGFR and categorical albuminuria (ACR: 2 plus ACR <30 mg/g or dipstick −/±. Dots represent statistically significant and triangles represent not significant. The estimated HR and 95% CI at eGFR 120 with dipstick ≥++ for CVD mortality were omitted, since only two studies contributed to reliable estimation. To convert ACR in mg/g to mg/mmol multiply 0.113.

Source: PubMed

3
Subscribe